Alnylam plans to appeal ruling on patents related to Moderna COVID vaccine

Published On 2023-08-28 06:00 GMT   |   Update On 2023-08-28 06:00 GMT

Bengaluru: Alnylam Pharmaceuticals has said it plans to appeal a ruling by the U.S. District Court for the District of Delaware on two patents asserted against Moderna for the latter's COVID-19 vaccine Spikevax.Cambridge, Massachusetts-based Alnylam sued both Moderna and Pfizer Inc in Delaware last year, seeking royalties for the lipid nanoparticle (LNP) technology their vaccines use to...

Login or Register to read the full article

Bengaluru: Alnylam Pharmaceuticals has said it plans to appeal a ruling by the U.S. District Court for the District of Delaware on two patents asserted against Moderna for the latter's COVID-19 vaccine Spikevax.

Cambridge, Massachusetts-based Alnylam sued both Moderna and Pfizer Inc in Delaware last year, seeking royalties for the lipid nanoparticle (LNP) technology their vaccines use to deliver genetic material known as mRNA.
The cases are part of a wave of patent lawsuits that have been filed over technology used in the COVID-19 shots, including one filed by Moderna against Pfizer last year.
While Alnylam and Moderna have jointly agreed to final judgment over the non-infringement of two patents, Alnylam said it disagrees with the court's ruling.
Alnylam anticipates its second action against Moderna for infringement will move forward in the Delaware Court.
Moderna did not immediately respond to a request for comment.
The Delaware court's ruling did not impact the company's infringement contentions in its two separate suits against Pfizer, Alnylam said.




Tags:    
Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News